Effect of Gemcitabine on Cancer Growth
Author Information
Author(s): E. Boven, H. Schipper, C.A.M. Erkelens, S.A. Hatty, H.M. Pinedo
Primary Institution: Free University Hospital, Amsterdam, The Netherlands
Hypothesis
The study investigates how the schedule and dose of gemcitabine affect its anti-tumor efficacy in human cancer models.
Conclusion
Gemcitabine shows significant anti-tumor effects in soft tissue sarcoma and ovarian cancer, with efficacy influenced by the treatment schedule.
Supporting Evidence
- The weekly schedule of gemcitabine induced over 50% growth inhibition in several cancer lines.
- Gemcitabine was more effective than conventional drugs in some tumor lines.
- Different schedules of administration resulted in varying levels of toxicity and efficacy.
Takeaway
Gemcitabine is a medicine that helps fight cancer, and how often and how much you take it can change how well it works.
Methodology
The study used various doses and schedules of gemcitabine in human cancer xenografts grown in nude mice to assess its efficacy.
Limitations
The study was conducted in animal models, which may not fully replicate human responses.
Participant Demographics
Female NMRI/Cpb nude mice were used in the experiments.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website